Overview

Detailed Summary

Amanta Healthcare Limited is a fully integrated sterile liquids pharmaceutical manufacturer and marketer focused on Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), using ABFS and ISBM technologies from a WHO‑GMP certified facility in Gujarat, with a 47-product portfolio, 320 distributors, and exports to 21 countries.
The company is mid-inflection: FY25 revenues were INR275 crore and PAT turned positive to INR11 crore after prior losses, with a historical revenue CAGR of 11.8% (FY21–25); management targets a materially higher 20%+ CAGR over the next two years driven by capacity additions and product mix improvement.
SteriPort®, Amanta’s differentiated two‑port ISBM polypropylene container, is the core revenue driver at ~40–44% of revenues and operates at high utilization (91%), giving the company pricing discipline, perceived sterility advantages over polyethylene containers, and a leadership position in the two‑port IV fluids niche.
Near-term value drivers are capital‑led and operational: a large FY26 capex program (~INR130 crore) to add SteriPort and SVP capacity, plus a 10.8 MW captive solar plant (INR34.8 crore) expected to save ~INR9 crore annually, combined with a conservative FY27 revenue target near INR400 crore and margin expansion to mid‑20s percent EBITDA.
Balance sheet momentum is visible: the company has reduced borrowings and debt‑to‑equity materially from FY23 levels, repaid higher‑coupon instruments, completed an IPO and private placement (INR20 crore), and is prioritizing accelerated deleveraging even while funding expansion.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Market Cap: 388 Cr
Volatility: Moderate Risk
P/E Ratio: 27.0
Industry P/E: 28.0
PEG Ratio: 0.1
P/B Ratio: 1.8
52W High: 154.85
52W Low: 95.05

Sales CAGR

1Y: -2.01%
3Y: —
5Y: —
10Y: —

Profit CAGR

1Y: 189.26%
3Y: —
5Y: —
10Y: —

ROE

TTM: 7.41%
3Y: 5.33%
5Y: 14.84%
10Y: —

ROCE

TTM: 11.89%
3Y: 15.07%
5Y: 18.74%
10Y: —

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ALBERTDAVD	676.15	393 Cr	40.18	1.00	0.73	-3.83	-3.33	1.80
HALEOSLABS	1272.00	391 Cr	19.37	1.90	0.12	9.06	12.31	5.32
AMANTA	100.30	388 Cr	27.04	1.84	0.00	7.41	11.89	3.14
ZIMLAB	67.75	365 Cr	47.05	1.27	0.00	2.62	6.18	1.50
MEDICO	41.51	359 Cr	29.65	5.38	0.00	16.97	20.65	8.44
SOLARAPP1	291.00	349 Cr	—	2.16	0.00	—	—	0.00
TLL	268.00	320 Cr	16.07	3.55	0.00	22.08	17.36	7.60

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	68	67	68	72	65	71	74
Expenses	55	53	53	53	50	56	59
Operating Profit	13	14	15	19	15	15	15
OPM %	19.68	20.80	22.21	26.31	22.81	20.67	20.62
Other Income	0.15	0.21	0.87	0.16	0.96	-2.56	0.68
Interest	9.45	6.32	5.90	6.28	6.29	5.15	5.06
Depreciation	4.60	4.60	4.51	4.69	4.64	4.66	4.67
Profit Before Tax	-0.50	3.17	5.53	8.15	4.93	2.28	6.30
Tax %	28.00	28.71	22.60	26.87	28.80	46.93	26.51
Net Profit	-0.36	2.26	4.28	5.96	3.51	1.21	4.63
EPS in Rs	—	0.59	—	—	1.22	0.35	1.35

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Sales	259	280	275
Expenses	206	223	215
Operating Profit	53	57	60
OPM %	20.35	20.51	21.72
Other Income	3.57	1.27	1.39
Interest	35	34	28
Depreciation	18	20	18
Profit Before Tax	2.69	5.39	15
Tax %	178.46	32.58	28.60
Net Profit	-2.11	3.63	11
EPS in Rs	—	—	—
Dividend Payout %	0.00	0.00	0.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Equity Capital	27	27	29
Reserves	36	39	68
Borrowings	216	205	204
Other Liabilities	96	81	81
Total Liabilities	374	352	382
Fixed Assets	229	223	217
CWIP	8.80	5.41	6.55
Investments	3.47	3.72	7.72
Other Assets	133	120	150
Total Assets	374	352	382

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	33	62	43	58	47
Cash from Investing Activity	-16	-6.05	-6.53	-10	-24
Cash from Financing Activity	-18	-50	-42	-46	-23
Net Cash Flow	-0.18	5.50	-6.27	1.43	-1.32

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2024	Feb 2025	Jun 2025	Aug 2025	Sep 2025	Dec 2025
Promoters	85.52%	85.52%	63.56%	85.60%	63.56%	63.56%
FIIs	0.00%	0.00%	2.21%	0.00%	2.21%	1.10%
DIIs	14.48%	14.48%	12.22%	14.40%	12.22%	11.24%
Public	0.00%	0.00%	22.02%	0.00%	22.02%	24.10%
Total Shareholders	192	200	30,695	361	30,695	16,181

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.